Non-Hodgkin Lymphoma | Specialty

Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 14th 2021

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

FDA Approves Crizotinib for Pediatric and Young Adult ALK+ Anaplastic Large Cell Lymphoma

January 14th 2021

January 14, 2021 - The FDA has approved crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma.

CLL Paradigm Poised to Expand With Novel Therapies as Chemo Is Phased Out

January 13th 2021

James Gerson, MD, discusses how he navigates treatment selection for patients with chronic lymphocytic leukemia and exciting developments in the pipeline.

Ibrutinib/Rituximab Approved in Canada for CLL

January 13th 2021

January 13, 2021 - Health Canada has approved the combination of ibrutinib and rituximab for use in patients with treatment-naïve chronic lymphocytic leukemia.

COVID-19 Pandemic Restructures Care in CLL

January 12th 2021

As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.

Dr. Shah on the Rationale for Tandem Receptor CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 11th 2021

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

January 8th 2021

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.

BET Inhibitor CC-90010 Shows Activity in Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma

January 7th 2021

January 7, 2021 - The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin Lymphoma

January 6th 2021

Rajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.

Dr. Andorsky on the Results of a Subgroup Analysis of the MAGNIFY Trial in NHL

January 5th 2021

David J. Andorsky, MD, discusses the results of a subgroup analysis of the phase 3b MAGNIFY trial in relapsed/refractory non-Hodgkin lymphoma.

End of data

x